Virginia Retirement Systems Et Al Amicus Therapeutics, Inc. Transaction History

Virginia Retirement Systems Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 17, 2023	BUY	$9.89 - $12.7 $45,494 - $58,420	4,600 Added 21.9%	25,600 $313 Million
Q3 2022 May 16, 2023	SELL	$9.82 - $12.75 $198,364 - $257,550	-20,200 Reduced 49.03%	21,000 $219 Million
Q1 2022 Apr 21, 2022	BUY	$7.89 - $12.48 $2,367 - $3,744	300 Added 0.73%	41,200 $390,000
Q4 2021 Feb 03, 2022	SELL	$9.82 - $12.44 $45,172 - $57,224	-4,600 Reduced 10.11%	40,900 $472,000
Q3 2021 Oct 21, 2021	BUY	$8.74 - $11.84 $121,486 - $164,576	13,900 Added 43.99%	45,500 $435,000
Q2 2021 Aug 13, 2021	BUY	$8.71 - $10.72 $74,035 - $91,120	8,500 Added 36.8%	31,600 $305,000
Q1 2021 Apr 30, 2021	BUY	$9.2 - $23.86 $4,600 - $11,930	500 Added 2.21%	23,100 $228,000
Q4 2020 Feb 16, 2021	BUY	$13.47 - $24.89 $45,798 - $84,626	3,400 Added 17.71%	22,600 $522,000
Q3 2020 Nov 12, 2020	SELL	$12.89 - $15.89 $11,601 - $14,301	-900 Reduced 4.48%	19,200 $271,000
Q2 2020 Aug 12, 2020	BUY	$8.86 - $15.69 $178,086 - $315,369	20,100 New	20,100 $303,000

312

311M

467K

515K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.58B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.